Abstract
Fabry disease (FD) is an X-linked inborn error of glycosphingolipid catabolism that results from mutations in the alpha-galactosidase A (GLA) gene. Evaluating the enzymatic activity in male individuals usually performs the diagnosis of the disease, but in female carriers the diagnosis based only on enzyme assays is often inconclusive. In this work, we analyzed 568 individuals from 102 families with suspect of FD. Overall, 51 families presented 38 alterations in the GLA gene, among which 19 were not previously reported in literature. The alterations included 17 missense mutations, 7 nonsense mutations, 7 deletions, 6 insertions and 1 in the splice site. Six alterations (R112C, R118C, R220X, R227X, R342Q and R356W) occurred at CpG dinucleotides. Five mutations not previously described in the literature (A156D, K237X, A292V, I317S, c.1177_1178insG) were correlated with low GLA enzyme activity and with prediction of molecular damages. From the 13 deletions and insertions, 7 occurred in exons 6 or 7 (54%) and 11 led to the formation of a stop codon. The present study highlights the detection of new genomic alterations in the GLA gene in the Brazilian population, facilitating the selection of patients for recombinant enzyme-replacement trials and offering the possibility to perform prenatal diagnosis.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Desnick, R. J., Ioannou, Y. A. & Eng, C. M. Alpha-Galactosidase A deficiency: Fabry disease in The Metabolic and Molecular Bases of Inherited Disease, Springer: New York, (2001).
Schiffmann, R. Fabry disease. Pharmacol. Ther. 122, 65–77 (2009).
Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. Prevalence of lysosomal storage disorders. Jama 281, 249–254 (1999).
Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler et al. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill: New York,, (2002).
Puck, J. M. & Willard, H. F. X inactivation in females with X-linked disease. N. Engl. J. Med. 338, 325–328 (1998).
Desnick, R. J. & Sweeley, C. C. Fabry's disease: defective a-galactosidase A in The Metabolic Basis of Inherited Disease, McGraw-Hill: New York,, (1984).
Lyon, M. F. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190, 372–373 (1961).
Guffon, N. Clinical presentation in female patients with Fabry disease. J. Med. Genet. 40, e38 (2003).
Whybra, C., Kampmann, C., Willers, I, Davies, J., Winchester, B., Kriegsmann, J. et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J. Inherit. Metab. Dis. 24, 715–724 (2001).
Eng, C. M., Banikazemi, M., Gordon, R. E., Goldman, M., Phelps, R., Kim, L. et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68, 711–722 (2001).
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S. et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N. Engl. J. Med. 345, 9–16 (2001).
Schiffmann, R., Kopp, J. B., Austin, H. A., Sabnis, S., Moore, D. F., Weibel, T. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Jama 285, 2743–2749 (2001).
Eng, C. M., Niehaus, D. J., Enriquez, A. L., Burgert, T. S., Ludman, M. D. & Desnick, R. J. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum. Mol. Genet. 3, 1795–1799 (1994).
Kornreich, R., Desnick, R. J. & Bishop, D. F. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res. 17, 3301–3302 (1989).
Bishop, D. F., Calhoun, D. H., Bernstein, H. S., Hantzopoulos, P., Quinn, M. & Desnick, R. J. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc. Natl Acad. Sci. USA 83, 4859–4863 (1986).
Bishop, D. F., Kornreich, R. & Desnick, R. J. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc. Natl Acad. Sci. USA 85, 3903–3907 (1988).
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010).
Müller, K. B., Rodrigues, M. D. B., Pereira, V. G., Martins, A. M. & D’Almeida, V. Reference values for lysosomal enzymes activities using dried blood spots samples - a Brazilian experience. Diagn. Pathol. 5, 65 (2010).
Shabbeer, J., Yasuda, M., Benson, S. D. & Desnick, R. J. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum. Genomics. 2, 297–309 (2006).
Batista, E. C., Carvalho, L. R., Casarini, D. E., Carmona, A. K., dos Santos, E. L., da Silva, E. D. et al. ACE activity is modulated by the enzyme alpha-galactosidase A. J. Mol. Med. (Berl) 89, 65–74 (2011).
Ishii, S., Sakuraba, H. & Suzuki, Y. Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum. Genet. 89, 29–32 (1992).
Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H. et al. High incidence of later-onset fabry disease revealed by newborn screening. Am. J. Hum. Genet. 79, 31–40 (2006).
Okumiya, T., Ishii, S., Kase, R., Kamei, S., Sakuraba, H. & Suzuki, Y. Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins. Hum. Genet. 95, 557–561 (1995).
Meaney, C., Blanch, L. C. & Morris, C. P. A nonsense mutation (R220X) in the alpha-galactosidase A gene detected in a female carrier of Fabry disease. Hum. Mol. Genet. 3, 1019–1020 (1994).
Davies, J., Christomanou, H., Winchester, B. & Malcolm, S. Detection of 8 new mutations in the alpha-galactosidase A gene in Fabry disease. Hum. Mol. Genet. 3, 667–669 (1994).
Davies, J. P., Winchester, B. G. & Malcolm, S. Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum. Mol. Genet. 2, 1051–3 (1993).
Ashley, G. A., Shabbeer, J., Yasuda, M., Eng, C. M. & Desnick, R. J. Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype. J. Hum. Genet. 46, 192–196 (2001).
Blanch, L. C., Meaney, C. & Morris, C. P. A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene. Hum. Mutat. 8, 38–43 (1996).
Ploos van Amstel, J. K., Jansen, R. P., de Jong, J. G., Hamel, B. C. & Wevers, R. A. Six novel mutations in the alpha-galactosidase A gene in families with Fabry disease. Hum. Mol. Genet. 3, 503–505 (1994).
Bernstein, H. S., Bishop, D. F., Astrin, K. H., Kornreich, R., Eng, C. M., Sakuraba, H. et al. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J. Clin. Invest. 83, 1390–1399 (1989).
Eng, C. M., Ashley, G. A., Burgert, T. S., Enriquez, A. L., D’Souza, M. & Desnick, R. J. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol. Med. 3, 174–182 (1997).
Blaydon, D., Hill, J. & Winchester, B. Fabry disease: 20 novel GLA mutations in 35 families. Hum. Mutat. 18, 459 (2001).
Barker, D., Schafer, M. & White, R. Restriction sites containing CpG show a higher frequency of polymorphism in human DNA. Cell 36, 131–138 (1984).
Gan, J., Zhang, Y. L., Carter, K. B., Cauthron, R. D. & Steinberg, R. A. On the spontaneous mutability of CpG sites in cultured S49 mouse lymphoma cells. Somat. Cell. Mol. Genet. 25, 129–145 (1999).
Cooper, D. N. & Youssoufian, H. The CpG dinucleotide and human genetic disease. Hum. Genet. 78, 151–155 (1988).
Cullen, C. R., Hubberman, P., Kaslow, D. C. & Migeon, B. R. Comparison of factor IX methylation on human active and inactive X chromosomes: implications for X inactivation and transcription of tissue-specific genes. EMBO J. 5, 2223–2229 (1986).
Gartler, S. M. & Riggs, A. D. Mammalian X-chromosome inactivation. Annu. Rev. Genet. 17, 155–190 (1983).
Yen, P. H., Patel, P., Chinault, A. C., Mohandas, T. & Shapiro, L. J. Differential methylation of hypoxanthine phosphoribosyltransferase genes on active and inactive human X chromosomes. Proc. Natl. Acad. Sci. USA 81, 1759–1763 (1984).
Shabbeer, J., Yasuda, M., Luca, E. & Desnick, R. J. Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype. Mol. Genet. Metab. 76, 23–30 (2002).
Garman, S. C. & Garboczi, D. N. Structural basis of Fabry disease. Mol. Genet. Metab. 77, 3–11 (2002).
Ashton-Prolla, P., Ashley, G. A., Giugliani, R., Pires, R. F., Desnick, R. J. & Eng, C. M. Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG). Am. J. Med. Genet. 84, 420–424 (1999).
Pereira, F. S., Jardim, L. B., Netto, C. B., Burin, M. G., Cecchin, C., Giugliani, R. et al. Genomic analysis of Brazilian patients with Fabry disease. Braz. J. Med. Biol. Res. 40, 1599–1604 (2007).
Acknowledgements
This work was supported by grants from FAPESP (2008/06676-8). VD’A and JBP are recipients from fellowships from CNPq, Brazil. We would like to thank all the physicians that helped the accomplishment of this work, providing the samples analyzed in this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Turaça, L., Pessoa, J., Motta, F. et al. New mutations in the GLA gene in Brazilian families with Fabry disease. J Hum Genet 57, 347–351 (2012). https://doi.org/10.1038/jhg.2012.32
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2012.32
Keywords
This article is cited by
-
Effects of agalsidase-β administration on vascular function and blood pressure in familial Anderson–Fabry disease
European Journal of Human Genetics (2021)
-
Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations
Metabolic Brain Disease (2021)
-
Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients
Advances in Rheumatology (2020)
-
Oxidative stress biomarkers in Fabry disease: is there a room for them?
Journal of Neurology (2020)
-
Fabry disease in the Spanish population: observational study with detection of 77 patients
Orphanet Journal of Rare Diseases (2018)
